On January 8, according to the official website of the Ministry of Industry and Information Technology (MIIT), eight departments, including the MIIT, the Cyberspace Administration of China, the National Development and Reform Commission, the Ministry of Education, the Ministry of Commerce, the State-owned Assets Supervision and Administration Commission of the State Council, the State Administration for Market Regulation, and the National Data Bureau, jointly issued the "Implementation Opinions on the Special Action for 'Artificial Intelligence + Manufacturing'," aiming to accelerate the industrialization and commercialization of brain-computer interfaces.
The opinions propose accelerating the upgrade of intelligent terminals. It supports breakthroughs in technologies such as on-device models and development application toolchains, and aims to cultivate AI terminals including smartphones, computers, tablets, and smart home devices. Focusing on key scenarios like industrial inspections and remote medical care, the document calls for speeding up the industrialization and commercialization of new types of terminals such as augmented reality/virtual reality (AR/VR) wearables and brain-computer interfaces.
China Galaxy Securities pointed out that brain-computer interface technology is transitioning from the laboratory to industrial production. Recently, Neuralink, a company owned by Elon Musk, announced plans to initiate mass production of brain-computer interface devices in 2026 and advance fully automated surgical procedures.
The global brain-computer interface industry is experiencing rapid development, with its technical paths mainly divided into invasive and non-invasive types. The industry chain covers multiple fields including materials, chips, surgery, and medical rehabilitation. In recent years, a series of policies issued intensively from the national to local levels in China, along with supportive measures such as medical insurance pricing and priority approval, have clarified the direction for the brain-computer interface industry's development and provided strong guarantees for its commercialization and innovation catch-up in China.
Wanlian Securities released a research report stating that the policy opinions indicate an acceleration of the industrialization and commercialization process for brain-computer interfaces. Currently, the global competitive landscape of the brain-computer interface industry shows a pattern of "the US leading in invasive technologies, while China leads in non-invasive technologies," with competition focusing on three core elements: "electrodes, chips, and algorithms."
In the short term, commercialization of brain-computer interfaces will focus more on non-invasive methods. In the medium to long term, the core lies in comprehensive system capabilities involving upstream technologies like (semi-)invasive/invasive "flexible electrodes + high-throughput, low-power chips," multi-center clinical trials, and compliance standards. Factors such as industry policy support, medical insurance payment, breakthroughs in clinical registration milestones, core technological breakthroughs, and domestic substitution are all expected to be catalysts for the industry's future development.
Hong Kong-listed stocks related to brain-computer interfaces include: HeartCare-B (06609), NANJING PANDA (00553), LENS (06613), BrainAurora-B (06681), and MICROPORT NEURO (02172).
Comments